ロード中...
Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
Type 2 diabetes is increasing in prevalence worldwide, and hyperglycemia is often poorly controlled despite a number of therapeutic options. Unlike previously available agents, sodium-glucose co-transporter 2 (SGLT2) inhibitors offer an insulin-independent mechanism for improving blood glucose level...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Just Medical Media Limited
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4079288/ https://ncbi.nlm.nih.gov/pubmed/24991224 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212262 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|